DareonTM-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas

被引：0
|
作者：
Gambardella, Valentina
Greystoke, Alastair
Reck, Martin
Liu, Meiruo
Mueller, Martha
Duenzinger, Ulrich
Bergsland, Emily B.
Owonikoko, Taofeek
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-LB_A16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB_A16
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer
    Hirose, Takashi
    Nakashima, Masanao
    Shirai, Takao
    Kusumoto, Sojiro
    Sugiyama, Tomohide
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Ohnishi, Tsukasa
    Ohmori, Tohru
    Adachi, Mitsuru
    LUNG CANCER, 2011, 73 (03) : 345 - 350
  • [32] Anlotinib plus oral fluoropyrimidine S1 in treating patients with refractory or relapsed small cell lung cancer (SALTER TRIAL): An open-label, multicenter, single-arm, phase II trial
    Wang, W.
    Lv, D.
    Wu, X.
    Ye, J.
    Zhou, C.
    Wang, J.
    Ling, L.
    Yang, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1164 - S1164
  • [33] Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC)
    Beltran, Himisha
    Johnson, Melissa Lynne
    Jain, Prantesh
    Schenk, Erin L.
    Sanborn, Rachel E.
    Thompson, Jonathan Robert
    Dowlati, Afshin
    Mamdani, Hirva
    Aggarwal, Rahul Raj
    Anand, Banmeet S.
    Gramza, Ann W.
    Choudhury, Noura J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial
    Tan, Daryl
    Phipps, Colin
    Hwang, William Y. K.
    Tan, Soo Yong
    Yeap, Chun Hsien
    Chan, Yiong Huak
    Tay, Kevin
    Lim, Soon Thye
    Lee, Yuh Shan
    Kumar, Sathish Gopalakrishnan
    Ng, Soo Chin
    Fadilah, S.
    Kim, Won Seog
    Goh, Yeow Tee
    LANCET HAEMATOLOGY, 2015, 2 (08): : E326 - E333
  • [35] A phase II trial of gemcitabine and irinotecan in patients with refractory or relapsed non-small cell lung cancer.
    Ohyanagi, F
    Nishio, M
    Horai, T
    Kasahara, K
    Shibata, K
    Takeda, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 697S - 697S
  • [36] Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)
    Miller, AA
    Herndon, JE
    Gu, L
    Green, MR
    LUNG CANCER, 2005, 48 (03) : 399 - 407
  • [37] A multicenter, open-label, phase IIIB trial of erlotinib in patients with advanced non-small cell lung cancer
    Hainsworth, J
    Spigel, D
    O'Neill, V
    Klencke, B
    LUNG CANCER, 2005, 49 : S246 - S247
  • [38] A phase II, open-label, efficacy and safety of olaparib with bevacizumab (SUKSES-B2) in biomarker matched relapsed or refractory small cell lung cancer.
    Park, Sehhoon
    Kim, Jiyeon
    Mortimer, Peter G.
    Kim, Heejung
    Jung, Hyun Ae
    Sun, Jong-Mu
    Park, Woong-Yang
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Lee, Se-Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer
    Aggarwal, Charu
    Maity, Alisha P.
    Bauml, Joshua M.
    Long, Qi
    Aleman, Tomas
    Ciunci, Christine
    D'Avella, Christopher
    Volpe, Melissa
    Anderson, Evan
    Jones, Lisa McCormick
    Sun, Lova
    Singh, Aditi P.
    Marmarelis, Melina E.
    Cohen, Roger B.
    Langer, Corey J.
    Amaravadi, Ravi
    ONCOLOGIST, 2023, 28 (07): : 644 - +
  • [40] ERLOTINIB IN PROGRESSIVE PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II OPEN-LABEL TRIAL
    Piantedosi, Francovito
    Vitiello, Fabiana
    Spina, Sergio
    Zinno, Luigia
    D'Agostino, Diego
    Caputo, Francesca
    Gilli, Marina
    Hengeller, Mario
    Iacobelli, Simona
    Casale, Beniamino
    Caputi, Mario
    Marsico, Serafino A.
    Bianco, Andrea
    ANNALS OF ONCOLOGY, 2009, 20
12345